Can systemically administered antibiotics be detected in wound tissues and surfaces under negative pressure wound therapy?
interstitial fluid
moxifloxacin
negative pressure wound therapy (NPWT)
pharmacokinetics
wound infection
Journal
International wound journal
ISSN: 1742-481X
Titre abrégé: Int Wound J
Pays: England
ID NLM: 101230907
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
23
09
2018
revised:
09
12
2018
accepted:
11
12
2018
pubmed:
4
1
2019
medline:
6
8
2019
entrez:
4
1
2019
Statut:
ppublish
Résumé
In this study, we evaluated a new aspect of negative pressure wound therapy (NPWT) as an analytical tool for pharmacokinetic studies. Twenty-one patients with soft tissue defects scheduled to receive NPWT were included in this study. Concomitant to NPWT, all patients received intravenous moxifloxacin (MX). At different time intervals, blood plasma levels of MX were sampled and compared with synchronous concentrations of MX in the exudate obtained from the NPWT drainage system. Serial measurements were performed upon initiation of the therapy as well as in the steady state (after 5 days). At steady state, wound tissue was obtained intraoperatively. High-performance liquid-chromatography (HPLC) was used for analysis. At 1 hour post-administration, the exudate/plasma levels (mg/L) were 1.92/3.07; at 12 hours, 0.80/1.14; at 24 hours, 0.26/0.43; and at 120 hours (steady state), 0.42/0.47. There was a correlation between exudate and plasma levels reaching approximately 0.75. Until now, methods for pharmacokinetic studies concerning interstitial fluid are difficult to apply in the clinical context. The presented method showed limitations, but we believe that, after methodological improvements, measurements of substances in the interstitial fluid by means of NPWT are feasible.
Identifiants
pubmed: 30604928
doi: 10.1111/iwj.13063
pmc: PMC7948631
doi:
Substances chimiques
Anti-Bacterial Agents
0
Moxifloxacin
U188XYD42P
Types de publication
Journal Article
Langues
eng
Pagination
503-510Subventions
Organisme : Bayer Healthcare AG
Informations de copyright
© 2019 Medicalhelplines.com Inc and John Wiley & Sons Ltd.
Références
Eur Spine J. 2016 Apr;25(4):1021-8
pubmed: 25904413
Biomed Res Int. 2013;2013:763096
pubmed: 23819120
Obstet Gynecol. 2015 May;125(5):1205-1210
pubmed: 25932849
Plast Reconstr Surg. 2006 Jun;117(7 Suppl):121S-126S
pubmed: 16799379
Curr Probl Surg. 2014 Jul;51(7):301-31
pubmed: 24935079
J Antimicrob Chemother. 2008 Jun;61(6):1328-31
pubmed: 18353805
Int J Oral Maxillofac Surg. 2005 Jul;34(5):464-72
pubmed: 16053863
Eur J Obstet Gynecol Reprod Biol. 2017 Mar;210:334-341
pubmed: 28122314
Arzneimittelforschung. 1978;28(1):72-5
pubmed: 580203
J Chemother. 2006 Oct;18(5):485-9
pubmed: 17127224
Int J Antimicrob Agents. 2008 Jan;31(1):21-6
pubmed: 18054465
Clin Pharmacokinet. 1998 Feb;34(2):95-9
pubmed: 9515183
J Chemother. 2003 Dec;15(6):558-62
pubmed: 14998080
Antimicrob Agents Chemother. 1999 Oct;43(10):2345-9
pubmed: 10508004
Pharm Res. 1997 Mar;14(3):267-88
pubmed: 9098867
Hepatogastroenterology. 2013 Sep;60(126):1371-5
pubmed: 23933929
Int Wound J. 2019 Apr;16(2):503-510
pubmed: 30604928
J South Orthop Assoc. 1997 Winter;6(4):279-88
pubmed: 9434249
Acta Orthop. 2018 Feb;89(1):95-100
pubmed: 28914105
J Infect Dis. 1972 Nov;126(5):492-7
pubmed: 4197753
Antimicrob Agents Chemother. 2002 Dec;46(12):3724-30
pubmed: 12435668
J Antimicrob Chemother. 2006 Apr;57(4):789-92
pubmed: 16504997
Drugs. 2004;64(20):2347-77
pubmed: 15456331
Antimicrob Agents Chemother. 2003 Oct;47(10):3099-103
pubmed: 14506015
Ann Surg. 1978 Aug;188(2):202-8
pubmed: 686888
Int Wound J. 2017 Dec;14(6):909-914
pubmed: 28198150
Antimicrob Agents Chemother. 1981 May;19(5):826-30
pubmed: 7027924
J Chromatogr B Biomed Sci Appl. 1997 Nov 21;702(1-2):163-74
pubmed: 9449568